A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Krystexxa (pegloticase)(MIRROR Randomized Controlled Trial [RCT])
This Study is
No Longer Enrolling
Adult
18 years of age or older Uncontrolled gout- Serum Uric Acid 7mg/dL or higher Failure to maintain normalization of serum uric acid with xanthine oxidease inhibitor at the maximum medically appropriate dose or contraindication to xanthine oxidase inhibitors. Symptoms of gout- 1. Presence of at lease one tophus 2. Recurrent flares defined as 2 or more flares in the past 12 months 3. Presence of chronic gouty arthritis
IV - Research Studies occurring after FDA has approved a drug for marketing. These studies gather additional information about a drug's safety, efficacy, or optimal use.
Treatment
Barbara Davis Center
University of Colorado Hospital
Protocol Number: 19-1717
More information available at ClinicalTrials.gov: NCT03994731
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers